Dror plans to disrupt the aligner market by offering millions of people a revolutionary alternative to traditional aligners, based on the belief that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions. The company announced FDA 510(k) clearance for its next-generation ZSmile Platform on February 19, 2026, enabling a phased U.S. commercial launch.
Cyborg Score Rationale
Dror has achieved meaningful regulatory milestones (FDA 510(k) in February 2026, Israeli AMAR approval, prior CE marking), validating the ZSmile platform's clinical safety. However, the company trades OTC with a ~$18M market cap, minimal employees (4 as of March 2025), and large recent net losses, indicating early-stage commercial execution risk and significant capital constraints for scaling.
Top Insights
(February 2026) Achieved FDA 510(k) clearance for next-generation ZSmile platform, a major regulatory milestone enabling U.S. market entry
Proprietary pulsating air pneumatic technology represents differentiated approach vs. traditional mechanical aligners; tested in 300+ patients across CE and Israeli trials
Minimal operational infrastructure (4 employees as of March 2025) suggests heavy reliance on partnerships for manufacturing and commercialization
OTC-traded micro-cap with ~$18M market cap and recent quarterly losses (-$1.13M), indicating runway constraints despite regulatory progress
Named Competitors
Invisalign — Market-leading clear aligner system with extensive clinical evidence and provider network
SmileDirectClub — Direct-to-consumer clear aligner platform with telehealth integration
Byte — Hybrid teledentistry clear aligner service with accelerated treatment cycles
Recent Developments
(February 2026) FDA 510(k) clearance for next-generation ZSmile Platform announced
(September 2023) Changed company name from Novint Technologies, Inc. to Dror Ortho-Design, Inc. and updated ticker from NVNT to DROR
(2025-2026) Israeli Ministry of Health AMAR approval received and second-generation ZSmile platform transitioned from user experience trials to regulatory phase
Open the full interactive Dror Ortho-Design, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.